DCG-IV

DCG-IV
Systematic (IUPAC) name
(1R,2R)-3-[(1S)-1-amino-2-hydroxy-2-oxoethyl]cyclopropane-1,2-dicarboxylic acid
Identifiers
CAS Number 147782-19-2 YesY
PubChem CID 5310979
Chemical data
Formula C7H9NO6
Molar mass 203.149 g/mol
  (verify)

DCG-IV is a research drug which acts as a group-selective agonist for the group II metabotropic glutamate receptors (mGluR2/3).[1] It has potent neuroprotective and anticonvulsant effects in animal studies,[2][3][4][5] as well as showing anti-Parkinsonian effects,[6][7] but also impairs the formation of memories.[8][9]

References

  1. ↑ Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (August 1993). "A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord". British Journal of Pharmacology 109 (4): 1169–77. doi:10.1111/j.1476-5381.1993.tb13745.x. PMC 2175774. PMID 8401927.
  2. ↑ Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (April 1994). "Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death". European Journal of Pharmacology 256 (1): 109–12. doi:10.1016/0014-2999(94)90624-6. PMID 7517889.
  3. ↑ Yoshioka H, Sugita M, Kinouchi H (September 2009). "Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia". Neuroscience Letters 461 (3): 266–70. doi:10.1016/j.neulet.2009.06.056. PMID 19549561.
  4. ↑ Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (September 1998). "Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)". Brain Research 805 (1-2): 138–43. doi:10.1016/S0006-8993(98)00698-2. PMID 9733953.
  5. ↑ Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (December 2006). "Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury". Journal of Clinical Neuroscience 13 (10): 1023–7. doi:10.1016/j.jocn.2005.11.042. PMID 17113985.
  6. ↑ Dawson L, Chadha A, Megalou M, Duty S (February 2000). "The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat". British Journal of Pharmacology 129 (3): 541–6. doi:10.1038/sj.bjp.0703105. PMC 1571875. PMID 10711353.
  7. ↑ Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). "DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury". Neuroscience 113 (4): 857–69. doi:10.1016/S0306-4522(02)00232-4. PMID 12182892.
  8. ↑ Huang LQ, Rowan MJ, Anwyl R (February 1997). "mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro". NeuroReport 8 (3): 687–93. doi:10.1097/00001756-199702100-00022. PMID 9106748.
  9. ↑ Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (February 2004). "Inhibitory effects of group II mGluR-related drugs on memory performance in mice". Physiology & Behavior 80 (5): 747–58. doi:10.1016/j.physbeh.2003.12.010. PMID 14984810.


This article is issued from Wikipedia - version of the Friday, January 29, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.